Alder BioPharmaceuticals Inc. (NASDAQ:ALDR)’s share price was up 4.2% on Wednesday . The company traded as high as $26.22 and last traded at $26.14, with a volume of 314,118 shares. The stock had previously closed at $25.08.

A number of equities analysts have recently weighed in on ALDR shares. Credit Suisse Group AG reiterated an “outperform” rating and set a $40.00 target price on shares of Alder BioPharmaceuticals in a research note on Tuesday, March 29th. Brean Capital started coverage on Alder BioPharmaceuticals in a research report on Wednesday, April 20th. They set a “buy” rating and a $45.00 price target on the stock. Jefferies Group reissued a “buy” rating on shares of Alder BioPharmaceuticals in a research report on Thursday, June 30th. Zacks Investment Research downgraded Alder BioPharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, June 28th. Finally, Leerink Swann reissued an “outperform” rating on shares of Alder BioPharmaceuticals in a research report on Tuesday, March 29th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $52.00.

The company’s market cap is $1.31 billion. The stock has a 50 day moving average price of $27.62 and a 200 day moving average price of $25.71.

Alder BioPharmaceuticals (NASDAQ:ALDR) last issued its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.72) by $0.04. During the same quarter in the previous year, the company earned ($0.40) EPS. On average, analysts forecast that Alder BioPharmaceuticals Inc. will post ($3.25) EPS for the current fiscal year.

In related news, CEO Randall C. Schatzman sold 30,000 shares of the stock in a transaction dated Monday, April 18th. The shares were sold at an average price of $28.07, for a total value of $842,100.00. Following the completion of the transaction, the chief executive officer now directly owns 124,409 shares of the company’s stock, valued at $3,492,160.63. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Randall C. Schatzman sold 10,000 shares of the stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $28.02, for a total transaction of $280,200.00. Following the completion of the transaction, the chief executive officer now directly owns 115,933 shares of the company’s stock, valued at $3,248,442.66. The disclosure for this sale can be found here.

A number of institutional investors recently added to or reduced their stakes in ALDR. ProShare Advisors LLC increased its position in Alder BioPharmaceuticals by 8.6% in the fourth quarter. ProShare Advisors LLC now owns 38,476 shares of the biopharmaceutical company’s stock worth $1,271,000 after buying an additional 3,058 shares during the last quarter. Nationwide Fund Advisors increased its position in Alder BioPharmaceuticals by 103.6% in the fourth quarter. Nationwide Fund Advisors now owns 30,380 shares of the biopharmaceutical company’s stock worth $1,003,000 after buying an additional 15,457 shares during the last quarter. Pyrrho Capital Management LP increased its position in Alder BioPharmaceuticals by 205.0% in the fourth quarter. Pyrrho Capital Management LP now owns 63,000 shares of the biopharmaceutical company’s stock worth $2,081,000 after buying an additional 42,343 shares during the last quarter. California Public Employees Retirement System increased its position in Alder BioPharmaceuticals by 834.5% in the fourth quarter. California Public Employees Retirement System now owns 81,300 shares of the biopharmaceutical company’s stock worth $2,685,000 after buying an additional 72,600 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in Alder BioPharmaceuticals by 290.6% in the fourth quarter. Wells Fargo & Company MN now owns 269,774 shares of the biopharmaceutical company’s stock worth $8,911,000 after buying an additional 200,707 shares during the last quarter.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.